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Progressive thickening of the aortic valve leaflets and narrowing 
of the aortic annulus leads to increased mechanical stress on 
the left ventricle and reduces cardiac output, resulting in further 
complications.1–3 The proportion of the population affected increases 
as the median age of a country or region rises. Approximately 2–4 % 
of people aged over 65 will develop calcific aortic stenosis, with 
25 % of people in this age group presenting with signs of the disease, 
leading to a 50  % increased risk of cardiovascular related events. 
Furthermore, there is an associated risk of 80  % over 5 years of 
progression to heart failure, aortic valve replacement or death.4
Anatomy and Histology
The normal aortic valve maintains unidirectional blood flow from 
the left ventricle into the aorta. It is a supple membrane that opens 
and closes with each heartbeat more than 100,000 times a day. 
The healthy aortic valve comprises three leaflets and is located 
at the junction between the left ventricular outflow tract and the 
aortic root. 
The internal collagen framework of the leaflets is arranged in three 
distinct layers, which – from the aortic to ventricular surface – are 
the fibrosa, spongiosa, and ventricularis (see Figure 1). This leaflet 
structure is covered on both the ventricular and aortic surfaces by 
endothelium in continuity with both the ventricular endocardium and 
the aortic endothelium. Each layer of the aortic valve has a distinct 
structure and function. The fibrosa, with its dense connective tissue, 
contains circumferentially oriented collagen fibres that provide most 
of the strength of the leaflets. The spongiosa is found at the bases of 
the leaflets. It contains a loose matrix of mucopolysaccharides, 
and provides a cushion to resist compressive forces and facilitate 
movements between the fibrosa and ventricularis during leaflet 
motion. The ventricularis layer contains radially oriented elastin and 
contributes to flexibility, allowing for changes in leaflet shape during 
opening and closing. Under normal conditions, all three layers are 
avascular with no cellular infiltrates and are innervated by adrenergic 
and cholinergic neural networks.5–7 To remain pliable, the aortic valve 
must undergo continuous repair throughout life. Accumulation of 
fibrotic tissue and calcium in a valve leads to decreased pliability and 
narrowing of the valve orifice.8,9 
Valve interstitial cells (VICs) are found in each of these layers, and 
have distinct sub-populations that regulate homeostasis within the 
valve leaflets.10–12 In addition to the common tricuspid anatomy of 
the aortic valve, a congenital bicuspid valve is found in 0.5–1.4  % 
of the general population, giving rise to differential biomechanical 
forces – both on the valve and the aortic wall.13–15 
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Pathophysiology and Mechanism of Calcification
Over the past several decades, the aetiology of calcific aortic valve 
disease (CAVD) has changed considerably. The lower prevalence of 
rheumatic heart disease and increased longevity in industrialised 
countries has resulted in a pattern shift from rheumatic to degenerative 
calcification as the most common cause of CAVD and subsequent 
calcific aortic stenosis.16–18 CAVD is the third most common heart 
disease in the western world,19 following coronary heart disease and 
hypertension. Its prevalence in the elderly (≥65 years of age) ranges 
from 2–4 % when considering only severe aortic stenosis, increasing 
to 25 % when aortic sclerosis is included.9 However, a relative minority 
of elderly individuals develop aortic valve calcification, suggesting 
pathological influences other than age play a role.
Calcific aortic stenosis is the second most prevalent cause for 
heart surgery and is responsible for approximately 15,000 deaths 
annually in North America.18 Calcific aortic stenosis is a well-known 
disease entity and we are able to assess numerous haemodynamic 
parameters using cardiac catheterisation or ultrasonography as well 
as cardiac computed tomography and cardiac magnetic resonance 
imaging.20 In CAVD, calcified nodules are initially observed at the 
base of the cusps and their presence gradually extends towards 
the orifice. All three cusps are usually usually affected, but one or 
more may be dominant. When blood flow through the stenotic aortic 
orifice becomes significantly restricted, haemodynamic impairment 
associated with serious symptoms of congestive heart failure 
and sudden cardiac death may occur. Severe symptomatic aortic 
stenosis is a Class I indication for surgical valve replacement 
according to the American Heart Association and American College 
of Cardiology guidelines for valvular heart disease.21 
CAVD is currently considered as an actively regulated and progressive 
disease, characterised by a cascade of cellular changes that initially 
cause fibrotic thickening, followed by extensive calcification of the 
aortic valve leaflets. This in turn leads to significant aortic valve stenosis 
and eventual left ventricular outflow obstruction (see Figure 2),10,22 for 
which surgical replacement remains the only viable treatment option. 
Currently there is no approved pharmacological treatment to stop the 
progression of CAVD.23 Descriptive studies using human specimens 
have demonstrated the hallmark features of this disease, including 
early atherosclerosis, cell proliferation and osteoblast expression. 24–26
CAVD and Traditional Risk Factors  
for Atherosclerosis
Aortic valve stenosis was first described by Lazare Riviere in 1663.27 
In the early 1900s, eminent pathologists such as Monckeberg, 
described CAVD as a passive degenerative process associated with 
rheumatic fever or aging, during which serum calcium attaches to the 
valve surface and binds to the leaflet to form nodules.28
In more recent decades, several studies have implicated the traditional 
risk factors for cardiovascular atherosclerosis in the development of 
CAVD. Atherosclerosis is a complex and multifactorial process that 
produces a lesion composed of lipids,29,30 macrophages,31 proliferating 
smooth muscle cells32 and apoptosis.33 It is regulated by endothelial 
nitric oxide synthase,34–38 and over time causes occlusion of the 
vessel diameter. Total cholesterol, increased low-density lipoprotein 
(LDL) cholesterol, increased lipoprotein(a), increased triglycerides, 
decreased high-density lipoprotein cholesterol, male sex, cigarette 
smoking, hypertension, and diabetes mellitus have been reported to 
increase the incidence of aortic stenosis, and are likely contribute 
to endothelial dysfunction and leaflet damage.2,3,39–43 The presence of 
LDL and atherosclerosis in calcified valves in surgical pathological 
studies supports the hypothesis of a common cellular mechanism.44,45 
Furthermore, patients with familial hypercholesterolaemia develop 
aggressive peripheral vascular disease, coronary artery disease and 
aortic valve lesions, which calcify with age.39,46–48 
Oxidised LDL (oxLDL) is implicated in vascular calcification associated 
with atherosclerosis.49,50 Elevated blood levels of oxLDL correlate with 
aortic valve calcification and fibrosis,51 and oxLDL accumulation in 
calcific, stenotic aortic valves is well described.52–56 Metabolic bone 
diseases – including Paget’s disease, secondary hyperparathyroidism 
and renal disease – as well as increased serum creatinine and calcium 
are also linked to progression of valve calcification, but include only a 
relative minority of patients who have aortic stenosis.57–59 Understanding 
of these clinical risk factors provides the foundation for cellular studies 
and the potential for targeted medical therapies for this disease, similar 
to vascular atherosclerosis. However, the overall evidence indicated 
by the presence of atherosclerotic risk factors may partly explain why 
Figure 1: Cellular Architecture of the Aortic Valve
Figure 2: Inflammatory Process of Calcific Aortic Stenosis
Valve endothelial cells (VECs) line the outer surface of the valve and function as a barrier to 
limit inflammatory cell infiltration and lipid accumulation. The three middle layers of the valve 
are the fibrosa, spongiosa, and ventricularis. These layers contain valve interstitial cells (VICs) 
as the predominant cell type. The fibrosa is nearest the aortic side of the valve, contains Type 
I and Type III fibrillar collagen, and serves a load-bearing function. The spongiosa contains 
glycosaminoglycans (GAGs) that lubricate the fibrosa and ventricularis layers as they shear 
and deform during the cardiac cycle. The ventricularis contains elastin fibres to decrease 
radial strain. Source: Rajamannan, 2011.10
A: Progression of histological changes during the process of calcific aortic stenosis. B: 
Tricuspid aortic valve, showing increasing deposition of calcium and reduction of the aortic 
annulus. BMP = bone morphogenetic protein; LDL = low-density lipoprotein; TNF = tumour 
necrosis factor; TGF = transforming growth factor. Source: Otto, 2008.22
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some patients who have congenitally abnormal valves develop aortic 
stenosis and require valve replacement sooner than those without risk 
factors. If atherosclerotic risk factors are important in the development 
of valvular heart disease, then experimental models of atherosclerosis 
are important in the understanding of this process. Studies in mice 
and rabbits have confirmed that experimental hypercholesterolaemia 
causes both atherosclerosis and calcification in the aortic valves.60–64 
Two months of cholesterol diet treatment in an experimental rabbit 
model induced marked thickening and complex calcification in the aortic 
valve leaflets. The model was extended to test the pharmacological 
effect of atorvastatin and angiotensin receptor antagonists on the 
inhibition of atherosclerosis pathways and calcification.65–69 Other 
pathways, such as Wnt signalling and increased calcium concentration 
via kallikrein-kinin signalling, are involved in CAVD. Wnt proteins interact 
with trans-membrane receptors, in particular LDL receptors, and inhibit 
the effect of the degradation of the intracellular protein β catenin. 
In turn, β catenins mediate osteoblastic transformation of VICs and 
bone production. In vitro, atorvastatin – an inhibitor of LDL-cholesterol in 
blood – can neutralise this signal pathway in mice models.66,70–72
The molecular and cellular processes that contribute to aortic valve 
stenosis are not fully characterised, but could provide insights into 
the development of new therapeutic approaches. 
Heart valves comprise a heterogeneous population of valvular 
endothelial cells and VICs, which maintain valve homeostasis and 
structural leaflet integrity. VICs, the most abundant cell type in 
the heart valve, play a key role in CAVD progression. 73 Various VIC 
phenotypes have been identified in diseased human heart valves,74 
including quiescent fibroblast-like VICs, which upon pathological cues 
can differentiate into activated myofibroblast-like VICs; and osteoblast-
like VICs, which are responsible for the active deposition of calcium in 
CAVD.53,62,74 Additionally, several studies have demonstrated the ability 
of VICs to undergo osteogenic differentiation.26,67,75
CAVD and Shear Stress
Although atherosclerotic coronary artery disease and CAVD share 
common features, they do have differences in rheology. This difference 
may provide at least a partial explanation for the differences in 
pathophysiology and response to therapy.76–80 CAVD is characterised by 
pulsatile shear stress on the ventricular side and low and reciprocating 
shear stress on the aortic side,81 whereas the coronary artery is 
exposed to sustained laminar blood flow under normal circumstances.82 
As stenosis progresses, wall shear stress across the aortic valve 
dramatically increases.76 Ahamed and colleagues have demonstrated 
that in vitro shear stress can activate latent transforming growth factor 
(TGF)-β1,82 a critical pro-fibrotic growth factor that can induce fibrosis 
and calcification.83 They also showed that active TGF-β1 could be eluted 
from thrombi formed in response to vascular injury in the carotid artery 
of mice where partial occlusion may have led to high local shear stress.82 
Subsequently, Albro et al. independently confirmed that shear stress can 
activate latent TGF-β1 in synovial fluid.83 These data raise the possibility 
of an association between the activation of circulating latent TGF-β1 
under high shear stress and the development of CAVD. Because platelets 
contribute ~45  % of the baseline circulating TGF-β1 level84 and have 
40–100 times more latent TGF-β1 than any other cells,85 it is possible that 
shear stress has two separate effects – inducing release of latent TGF-β1 
from platelets and activating the released latent TGF-β1. This mechanism 
may contribute to the progression of CAVD, because aortic valve 
narrowing increases shear stress resulting in greater release of platelet 
TGF-β1 and TGF-β1 activation. This in turn may lead to progressive valve 
narrowing and fibrosis, and thus even greater shear stress. 
Calcifying valves initially have macrophage and T-cell infiltrates as 
a result of endothelial injury.74 Bone morphogenetic protein (BMP)-2 
and BMP-4 are then expressed by myofibroblasts and preosteoblasts 
adjacent to these lymphocytic infiltrates.74 Furthermore, cardiac valves 
express markers of osteoblastic differentiation, including core-binding 
factor alpha 1 and osteocalcin.26 These valves also calcify in a manner 
similar to osteogenesis, with lamellar bone evident in the majority of 
pathological specimens examined.85 Congenitally bicuspid aortic valves 
uniformly show signs of calcification by the time individuals reach age 
30,86 which may, in part, be attributable to the particular mechanical 
stressors to which these valves are subjected.87 Recently, the molecular 
mechanism underlying bicuspid aortic valve calcification was solved. 
Mutations in the transcriptional regulator NOTCH1 resulted in aortic 
valve anomalies and severe calcification, owing to impaired repression 
of the osteoblast stimulator runt-related transcription factor 2 (RUNX2).88
Recent evidence suggests that CAVD is the result of an active 
inflammatory process affecting the valve and leading to osteoblastic 
transformation with bone formation of VICs by activation of the 
receptor activator of nuclear factor-κB (RANK).89
Regulatory Pathways 
There is increasing evidence that regulatory pathways that control 
heart valve development also are active with valve pathogenesis 
later in life. CAVD includes the activation of VICs in addition to 
increased expression of transcription factors that regulate the earliest 
events of valvulogenesis in the developing embryo.90 In addition to 
valve developmental pathways, regulatory proteins that promote the 
development of cartilage and bone lineages also are active in diseased 
valves.91 Thus, knowledge of the molecular regulatory pathways that 
control valve development will likely be informative in determining the 
molecular mechanisms of valve pathogenesis.
Aetiology 
CAVD has multifactorial aetiology. Many factors are centered on an 
inflammatory process affecting the valve and leading to calcification,74,85 
including deposition of LDLs,44,45 osteoblastic transformation with bone 
formation of valvular interstitial cells, connective tissue synthesis and 
tissue remodelling. On a microscopic level, the aortic leaflets contain 
disorganised collagen fibres, chronic inflammatory cells, extracellular 
bone matrix proteins, lipidic proteins and bone minerals.5 Calcification 
of the valve occurs following trans-differentiation of the VICs through a 
myofibroblast stage and into osteoblast cells.71,92
Half of adults undergoing aortic valve replacement have a bicuspid 
aortic valve associated, and nearly all of them will need to have a 
new valve inserted.93 Shear stress occurring with each cardiac systole 
is greater in a bicuspid valve than in a tri leaflet structure and these 
valves calcify earlier.93
Interestingly, the expression of RANK ligand (RANKL) by osteoblast 
cells will be actively involved in the activation and differentiation 
of osteoclast cells.89 RANKL levels normally rise with age and can 
predict cardiovascular events in humans, while osteoprotegerin 
(a physiological inhibitor of RANK) deficit can lead to vascular 
calcification in animal models.94,95 This study highlights an in vitro 
model to assess the mechanisms of aortic valve calcification.95
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Molecular Mechanisms of Calcification
The processes of aortic valve stenosis and calcification share 
many similarities with atherosclerosis, and the pathologies of both 
conditions have similar risk factors and histopathology.2 Activation 
of VICs and pathways of calcific aortic stenosis is the result of 
mechanical and shear stress, endothelial damage and deposition of 
LDLs, triggering inflammatory events and attracting inflammatory cells 
(monocytes, macrophages and T cells). 
These cells produce cytokines, including TGF-β, which regulates cell 
proliferation and differentiation; tumour necrosis factor-α, whose 
primary function is the regulation of the immune cells; and interleukin 
2, which is produced by activated T lymphocytes with growth 
factor activity.1 
VICs activated by the inflammatory process are designated 
myofibroblasts.5 These cells will develop angiogenic activity and 
produce matrix metalloproteinases, proteins that are involved in 
tissue remodelling and support VIC activation and transformation.96,97 
During this process activated VICs differentiate into osteoblasts. 
In Vitro Studies
Initial studies in our laboratory have involved the establishment 
and validation of porcine VIC isolation, culture and calcification 
procedures and the effect of denosumab on in vitro calcification. 
During the characterisation of porcine VICs, the first objective was to 
determine the expression level of a common marker of myofibroblast 
phenotype, α-actin, to demonstrate that active VICs were present in 
the samples. The expression of RUNX2, a major regulator of osteoblast 
differentiation, was analysed to corroborate that CardiologyCardiology 
the effect of the complete transdifferentiation of VICs had taken place 
and that the osteoblast phenotype was present. Furthermore, changes 
in the expression of TGF-β (a promoter of osteogenesis), were detected 
and recorded. Additionally, RhoA, a regulator of nodule formation in 
myofibroblasts, was analysed, followed by examining changes in the 
expression of RANKL, a key regulator of bone metabolism. Finally, 
calponin, a protein with potential capability to inhibit bone formation, 
was measured to complete the genetic studies. TGF-β can increase 
calcium and collagen deposition.98 It is known that TGF-β can also 
stimulate the expression of RANK on pre-osteoclastic cells, and in this 
way increase osteoclastic sensitivity to RANKL.99 RANKL is expressed 
in the membrane of osteoblasts and monocytes. As yet there is still 
no evidence that TGF-β promotes calcification in porcine VICs by 
increasing RANK expression levels.
Our recent unpublished studies demonstrated the upregulation of 
key molecules during the spontaneous calcification of porcine VICs 
with an increase of calcium, collagen and alkaline phosphatase (ALP) 
activity. In vitro calcification was determined using standard staining 
and enzyme activity assays. Calcification in pig VICs was induced with 
sodium phosphate. The cells expressed markers for both vascular 
smooth muscle cells and osteoblasts, suggesting a transdifferentiation 
of the phenotype. Upregulation of α-actin, RUNX2, TGF-β and RhoA 
and downregulation of calponin were noted, with no changes seen in 
RANKL expression. Sodium phosphate increased nodular formation by 
day 7 and ALP activity of porcine VICs by day 14. The findings suggest 
that porcine VICs may be a good model to study the process of CAVD.100
Denosumab as a Potential Inhibitor of VIC 
Calcification In Vitro
Denosumab is a human IgG2 monoclonal antibody designed to target 
RANKL,101 which is expressed on the membrane of the osteoblasts 
and osteoclasts. Denosumab is used in the treatment of osteoporosis. 
Additionally, owing to its mechanism that blocks the receptor RANKL, 
it neutralises the activation of RANK receptors on the membrane 
of pre-osteoclast cells.More research is needed to address the 
interaction between RANK receptor and denosumab in porcine VICs.
Our recent unpublished studies showed that 50  μg/mL denosumab 
inhibited induced calcium deposition to basal levels in porcine VIC 
culture.100 Although associated with bone loss and shown to reduce 
vascular calcification, the effect of denosumab on calcification of 
human VICs is unknown. Recently, denosumab has been shown to 
reduce calcium deposition in the aorta, although the mechanisms 
by which it affects ectopic calcification are poorly understood.102 
Furthermore, osteoprotegerin (a signalling protein receptor and a 
member of the tumour necrosis factor receptor family) has been 
shown to stop ectopic calcification in vitro via a similar mechanism 
to denosumab, but there is still not enough evidence of any effect in 
reverting the process of calcification. Osteprotegerin’s mechanism 
of action is to block RANKL-RANK receptor interaction.94,95 A fuller 
understanding of the mechanisms of action of denosumab may identify 
a novel therapeutic approach for clinical treatment, supplementing the 
current surgical approach. It should be noted that extrapolation of 
the results obtained in an in vitro porcine model to humans should 
be cautious, as species variations are likely to exist. Although it is not 
possible to include all mechanisms involved in CAVD in a single model, 
experimental models can contribute towards identifying the role 
several factors may play in the development of CAVD. n
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